Literature DB >> 15940298

siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain.

D R Thakker1, F Natt, D Hüsken, H van der Putten, R Maier, D Hoyer, J F Cryan.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely used antidepressant drugs that increase the extracellular levels of serotonin by blocking the reuptake activity of the serotonin transporter (SERT). Although SSRIs elevate brain serotonergic neurotransmission acutely, their full therapeutic effects involve neurochemical adaptations that emerge following chronic drug administration. The adaptive downregulation of SERT has recently been implicated in the therapeutic response of SSRIs. Interestingly, studies using SERT-knockout mice reveal somewhat paradoxical depression-related effects, probably specific to the downregulation of SERT during early development. However, the behavioral significance of SSRI-mediated downregulation of SERT during adulthood is still unknown. We investigated whether somatic gene manipulation, triggered by infusing short interfering RNA (siRNA) into the ventricular system, would enable the downregulation of SERT in the adult mouse brain. Infusing the SERT-targeting siRNA, for 2 weeks, significantly reduced the mRNA levels of SERT in raphe nuclei. Further, a significant, specific and widespread downregulation of SERT-binding sites was achieved in the brain. In contrast, 2-week infusion of the SSRI, citalopram, produced a widespread downregulation of SERT-binding sites, independent of any alterations at the mRNA level. Irrespective of their mechanisms for downregulating SERT in the brain, infusions of SERT-siRNA or citalopram elicited a similar antidepressant-related behavioral response in the forced swim test. These results signify a role for the downregulation of SERT in mediating the antidepressant action of SSRIs in adults. Further, these data demonstrate that siRNA-induced widespread knockdown of gene expression serves as a powerful tool for assessing the function of endogenous genes in the adult brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940298     DOI: 10.1038/sj.mp.4001687

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  44 in total

Review 1.  Role of rho kinase in the functional and dysfunctional tonic smooth muscles.

Authors:  Márcio A F de Godoy; Satish Rattan
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

2.  Activation of the mGlu7 receptor elicits antidepressant-like effects in mice.

Authors:  Agnieszka Palucha; Kinga Klak; Piotr Branski; Herman van der Putten; Peter J Flor; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2007-07-12       Impact factor: 4.530

3.  Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin.

Authors:  Y Zhang; M Landthaler; S D Schlussman; V Yuferov; A Ho; T Tuschl; M J Kreek
Journal:  Neuroscience       Date:  2008-10-02       Impact factor: 3.590

Review 4.  Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.

Authors:  David J Mc Carthy; Meenakshi Malhotra; Aoife M O'Mahony; John F Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

5.  Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.

Authors:  O Malkesman; D R Austin; T Tragon; I D Henter; J C Reed; M Pellecchia; G Chen; H K Manji
Journal:  Mol Psychiatry       Date:  2011-07-05       Impact factor: 15.992

6.  Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes.

Authors:  Ana M D Carneiro; David C Airey; Brent Thompson; Chong-Bin Zhu; Lu Lu; Elissa J Chesler; Keith M Erikson; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 8.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

9.  Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery.

Authors:  A M O'Mahony; B M D C Godinho; J Ogier; M Devocelle; R Darcy; J F Cryan; C M O'Driscoll
Journal:  ACS Chem Neurosci       Date:  2012-08-03       Impact factor: 4.418

10.  Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.

Authors:  Zaorui Zhao; Han-Ting Zhang; Elianna Bootzin; Mark J Millan; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.